{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:45:36Z","timestamp":1771047936613,"version":"3.50.1"},"reference-count":159,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019236","name":"Department of Radiology, Weill Cornell Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019236","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jgo.2024.101734","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T02:21:20Z","timestamp":1709259680000},"page":"101734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review"],"prefix":"10.1016","volume":"15","author":[{"given":"Nina Rosa","family":"Neuendorff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Yates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Devarakonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley E.","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0005","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2666-7568(21)00184-7","article-title":"Frailty assessment in the care of older people with haematological malignancies","volume":"2","author":"Goede","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0010","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.bbmt.2020.09.013","article-title":"Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age","volume":"26","author":"Flannelly","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0015","doi-asserted-by":"crossref","first-page":"617.e1","DOI":"10.1016\/j.jtct.2021.03.028","article-title":"Breaking the age barrier: physicians\u2019 perceptions of candidacy for allogeneic hematopoietic cell transplantation in older adults","volume":"27","author":"Mishra","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0020","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jgo.2024.101734_bb0025","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0040","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0045","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2024.101734_bb0055","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0060","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2024.101734_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0070","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41409-020-01159-9","article-title":"Autologous stem cell transplantation for multiple myeloma patients aged \u2265 75 treated with novel agents","volume":"56","author":"Vaxman","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0075","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bmt.2015.106","article-title":"High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma","volume":"50","author":"Wildes","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2024.101734_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.04.004","article-title":"Survival of elderly patients with multiple myeloma-effect of upfront autologous stem cell transplantation","volume":"62","author":"Merz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2024.101734_bb0090","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1182\/blood-2022-168888","article-title":"Similar benefits of high-dose melphalan based conditioning regimens followed by autologous hematopoietic cell transplantation in elderly myeloma population compared to the younger group: single center experience","volume":"140","author":"Nishihori","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10428194.2011.606942","article-title":"Feasibility of autologous hematopoietic stem cell transplant in patients aged \u226570 years with multiple myeloma","volume":"53","author":"Bashir","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.jgo.2024.101734_bb0100","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1080\/10428194.2019.1633633","article-title":"Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged \u226575 years","volume":"60","author":"Bashir","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0105","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jgo.2024.101734_bb0110","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1016\/j.clml.2021.05.002","article-title":"Trajectory of symptoms in patients undergoing autologous stem cell transplant for multiple myeloma: a population-based cohort study of patient-reported outcomes","volume":"21","author":"Ebraheem","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0115","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the connect\u00ae MM registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ajh.26596","article-title":"Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma","volume":"98","author":"D'Souza","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","article-title":"Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation","volume":"15","author":"Sherman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jgo.2024.101734_bb0130","series-title":"ASH Annual Meeting and Exposition","article-title":"Daratumumab plus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: Maia age subgroup analysis","author":"Thierry Facon","year":"2022"},{"key":"10.1016\/j.jgo.2024.101734_bb0135","series-title":"ASH Annual Meeting and Exposition","article-title":"Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma","author":"Elizabeth","year":"2019"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0140","doi-asserted-by":"crossref","first-page":"75.e1","DOI":"10.1016\/j.jtct.2021.09.024","article-title":"Benefits of autologous stem cell transplantation for elderly myeloma patients in the last quarter of life","volume":"28","author":"Joseph","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0145","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41409-020-01026-7","article-title":"Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma","volume":"56","author":"Lemieux","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.13804","article-title":"Autologous stem cell transplantation in multiple myeloma patients over 70 years: a GIMEMA Lazio working group experience in a retrospective case\u2013control study","volume":"109","author":"Rago","year":"2022","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jgo.2024.101734_bb0155","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/ejh.13861","article-title":"Conditioning with melphalan 200 mg\/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care","volume":"109","author":"Afram","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the myeloma XI trial","volume":"107","author":"Pawlyn","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age\u00a0\u2265\u00a065) with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.jgo.2024.101734_bb0175","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2024.101734_bb0180","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S2152-2650(21)02289-8","article-title":"P-162: compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients","volume":"21","author":"Delforge","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.jgo.2024.101734_bb0185","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1200\/JCO.21.00242","article-title":"Advances in management for older adults with hematologic malignancies","volume":"39","author":"Rosko","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2024.101734_bb0190","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2021-146650","article-title":"Fitness, a UK myeloma research Alliance (UK-MRA) frailty-adjusted therapy study, supports the feasibility of recruiting frail newly diagnosed myeloma patients to large clinical trials","volume":"138","author":"Cook","year":"2021","journal-title":"Blood"},{"issue":"10314","key":"10.1016\/j.jgo.2024.101734_bb0195","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0200","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41416-021-01367-0","article-title":"The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO)","volume":"124","author":"Lund","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0205","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2666-7568(20)30036-2","article-title":"The elderly functional index (ELFI), a patient-reported outcome measure of functional status in patients with cancer: a multicentre, prospective validation study","volume":"2","author":"Soo","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0215","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jgo.2020.10.019","article-title":"Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients","volume":"12","author":"Derman","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0220","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0225","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jgs.15715","article-title":"Geriatric assessment in older adults with multiple myeloma","volume":"67","author":"Wildes","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.6004\/jnccn.2023.0007","article-title":"NCCN guidelines\u00ae insights: hematopoietic cell transplantation, version 3.2022","volume":"21","author":"Saad","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0235","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","article-title":"High-dose melphalan (200mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (\u226565 years) myeloma patients: comparison with younger patients treated on the same protocol","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0240","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/leu.2011.131","article-title":"Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy","volume":"25","author":"Cavallo","year":"2011","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0245","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0250","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0255","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0260","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR\u00a0T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0265","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0270","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the collaboration to collect autologous transplant outcomes in lymphoma and myeloma (CALM) study. A report by the EBMT chronic malignancies working party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2024.101734_bb0275","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0280","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0285","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","article-title":"Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0290","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","article-title":"Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries","volume":"36","author":"R\u00e9cher","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0295","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgo.2020.11.001","article-title":"Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades","volume":"12","author":"Ihlow","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2024.101734_bb0300","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11899-019-00552-6","article-title":"Health-related quality of life and treatment of older adults with acute myeloid leukemia: a young international society of geriatric oncology review paper","volume":"14","author":"Loh","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"10.1016\/j.jgo.2024.101734_bb0305","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1634\/theoncologist.2018-0890","article-title":"Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists","volume":"24","author":"Loh","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0310","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0315","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.3324\/haematol.2021.279010","article-title":"Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial","volume":"107","author":"Russell","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2024.101734_bb0320","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H., et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood 140(12):1345\u20131377. doi:10.1182\/blood.2022016867.","DOI":"10.1182\/blood.2022016867"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0325","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.jgo.2024.101734_bb0330","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1182\/bloodadvances.2021006468","article-title":"Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and\/or secondary AML","volume":"6","author":"Uy","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0335","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbmt.2012.11.006","article-title":"Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients","volume":"19","author":"Muffly","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0340","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41409-017-0021-4","article-title":"Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis","volume":"53","author":"Deschler","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0345","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","article-title":"Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes","volume":"4","author":"Olin","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0350","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","article-title":"Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients","volume":"99","author":"Muffly","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0355","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/bmt.2015.180","article-title":"In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?","volume":"50","author":"Peffault de Latour","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0360","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","article-title":"Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors","volume":"8","author":"Guru Murthy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0365","doi-asserted-by":"crossref","first-page":"48.e1","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0370","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0375","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"25","key":"10.1016\/j.jgo.2024.101734_bb0380","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0385","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-018-0598-0","article-title":"Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60\u00a0years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT","volume":"11","author":"Santoro","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jgo.2024.101734_bb0390","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/01.HS9.0000848192.39196.d2","article-title":"P1332: promising outcome of patients older than 70 years who underwent peripheral blood haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia or high risk myelodysplastic syndrome","volume":"6","author":"Harbi","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.jgo.2024.101734_bb0395","doi-asserted-by":"crossref","first-page":"774.e1","DOI":"10.1016\/j.jtct.2021.05.024","article-title":"Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients","volume":"27","author":"Cho","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0400","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bbmt.2017.06.019","article-title":"Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome","volume":"23","author":"Slade","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jgo.2024.101734_bb0405","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jgo.2024.101734_bb0410","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/bloodadvances.2019000155","article-title":"Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70","volume":"3","author":"Imus","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0420","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0425","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0430","doi-asserted-by":"crossref","first-page":"662.e1","DOI":"10.1016\/j.jtct.2021.04.014","article-title":"Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse","volume":"27","author":"Newell","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0435","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0440","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial","volume":"97","author":"Beelen","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0445","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41409-022-01830-3","volume":"57","author":"Gavriilaki","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.jgo.2024.101734_bb0450","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0455","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the acute leukemia working party of the European group for blood and marrow transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0460","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/s41409-020-0839-z","article-title":"Premature ageing following allogeneic hematopoietic stem cell transplantation","volume":"55","author":"Uziel","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0465","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/jamaoncol.2016.0855","article-title":"Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study","volume":"2","author":"Arora","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jgo.2024.101734_bb0470","article-title":"Immune reconstitution in the aging host: opportunities for mechanism-based therapy in allogeneic hematopoietic cell transplantation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0475","first-page":"65","article-title":"Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis","volume":"3","author":"Small","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0480","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41375-018-0185-y","article-title":"The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Fein","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0485","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ki.2015.230","article-title":"A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010","volume":"88","author":"Mills","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0495","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.ajkd.2020.09.015","article-title":"Kidney function as risk factor and predictor of cardiovascular outcomes and mortality among older adults","volume":"77","author":"K\u00fchn","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jgo.2024.101734_bb0500","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.fct.2018.06.054","article-title":"Mechanism of cyclosporine a nephrotoxicity: oxidative stress, autophagy, and signalings","volume":"118","author":"Wu","year":"2018","journal-title":"Food Chem Toxicol"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0505","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002512-199915030-00003","article-title":"Cyclosporin pharmacokinetics in the elderly","volume":"15","author":"Kovarik","year":"1999","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0510","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.17835","article-title":"The clinical landscape of chronic graft-versus-host disease management in 2021","volume":"196","author":"Holtzman","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0515","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","article-title":"Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation","volume":"75","author":"Atkinson","year":"1990","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0520","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jgo.2024.101734_bb0525","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41409-022-01650-5","article-title":"Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis","volume":"57","author":"Maakaron","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jgo.2024.101734_bb0530","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbmt.2014.05.001","article-title":"Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease","volume":"20","author":"El-Jawahri","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0535","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","article-title":"Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy","volume":"27","author":"Ferrara","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jgo.2024.101734_bb0540","series-title":"Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten","author":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut","year":"2023"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0545","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3324\/haematol.2022.281407","article-title":"Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the elderly project of the Fondazione Italiana Linfomi (FIL)","volume":"108","author":"Tucci","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0550","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1016\/S2352-3026(21)00241-6","article-title":"A comprehensive approach to therapy of haematological malignancies in older patients","volume":"8","author":"Cordoba","year":"2021","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.jgo.2024.101734_bb0555","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jgo.2024.101734_bb0560","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0565","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2017-11-817775","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808","volume":"131","author":"Crump","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jgo.2024.101734_bb0570","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2019000102","article-title":"Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation","volume":"3","author":"Epperla","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0575","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clml.2020.05.008","article-title":"Real world outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma receiving palliative intent therapies","volume":"20","author":"Ayers","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0580","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","article-title":"Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis","volume":"27","author":"Kittai","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0585","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jgo.2024.101734_bb0590","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2024.101734_bb0595","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jgo.2024.101734_bb0600","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10297","key":"10.1016\/j.jgo.2024.101734_bb0605","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0610","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0615","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jgo.2024.101734_bb0620","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jgo.2024.101734_bb0625","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2024.101734_bb0630","first-page":"1","article-title":"Revising the treatment pathways in lymphoma: new standards of care-how do we choose?","volume":"42","author":"Ngu","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.jgo.2024.101734_bb0635","first-page":"233","article-title":"The international prognostic index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy","volume":"27","author":"Garcia-Recio","year":"2021","journal-title":"Transplant Cell Ther Off Publ Am Soc Transpl Cell Ther"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0640","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000817","article-title":"Outcome prediction in patients with large B-cell lymphoma undergoing chimeric antigen receptor T-cell therapy","volume":"7","author":"Voltin","year":"2023","journal-title":"HemaSphere"},{"issue":"23","key":"10.1016\/j.jgo.2024.101734_bb0645","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0650","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jgo.2024.101734_bb0655","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0660","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jgo.2024.101734_bb0665","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0670","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2024.101734_bb0675","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2022-156626","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma in transplant-ineligible patients: primary analysis of Alycante, a phase 2 Lysa study","volume":"140","author":"Houot","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jgo.2024.101734_bb0680","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0685","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0690","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"6382","key":"10.1016\/j.jgo.2024.101734_bb0695","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.jgo.2024.101734_bb0700","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0705","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0710","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0715","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jgo.2019.09.005","article-title":"Social support for older adults with cancer: young international society of geriatric oncology review paper","volume":"11","author":"Kadambi","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2024.101734_bb0720","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.624906","article-title":"It takes a team to make it through: the role of social support for survival and self-care after allogeneic hematopoietic stem cell transplant","volume":"12","author":"Song","year":"2021","journal-title":"Front Psychol"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2024.101734_bb0725","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood-2022-169872","article-title":"Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): a multicenter real-world evidence (RWE) study","volume":"140","author":"Shouse","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18810","article-title":"T in patients with large B-cell lymphoma not fit for autologous transplant","volume":"202","author":"Kuhnl","year":"2023","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.jgo.2024.101734_bb0735","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/bloodadvances.2023010003","article-title":"Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older lymphoma patients","volume":"7","author":"Lin","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jgo.2024.101734_bb0740","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.18054","article-title":"Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"197","author":"Roy","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jgo.2024.101734_bb0745","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"Supplement 1","key":"10.1016\/j.jgo.2024.101734_bb0750","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood-2021-149784","article-title":"Sarcopenia is a clinically relevant and independent predictor of health outcomes after chimeric antigen receptor T-cell therapy for lymphoma","volume":"138","author":"Iukuridze","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0755","doi-asserted-by":"crossref","first-page":"373","DOI":"10.6004\/jnccn.2022.7100","article-title":"Association between pretreatment skeletal muscle and outcomes after CAR T-cell therapy","volume":"21","author":"Lee","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0760","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jgo.2020.08.004","article-title":"Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies","volume":"12","author":"Jaggers","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2024.101734_bb0765","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41577-021-00646-4","article-title":"Immune ageing at single-cell resolution","volume":"22","author":"Mogilenko","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.jgo.2024.101734_bb0770","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2666-7568(21)00179-3","article-title":"Is cancer biology different in older patients?","volume":"2","author":"Van Herck","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"14","key":"10.1016\/j.jgo.2024.101734_bb0775","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2024.101734_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jgo.2024.101734_bb0785","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s43587-022-00198-9","article-title":"Multidimensional single-cell analysis of human peripheral blood reveals characteristic features of the immune system landscape in aging and frailty","volume":"2","author":"Luo","year":"2022","journal-title":"Nat Aging"},{"issue":"2","key":"10.1016\/j.jgo.2024.101734_bb0790","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.jgo.2024.101734_bb0795","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jgo.2024.101734_bb0800","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:57:54Z","timestamp":1761818274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406824000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1879406824000328"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2024.101734","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2024.101734","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101734"}}